Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
21 mai 2018 06h30 HE
|
Avenue Therapeutics
IV tramadol achieved primary and key secondary endpoints, as well as a clear dose response Initiation of second pivotal Phase 3 trial planned for third quarter of 2018 Management to host conference...
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
03 mai 2018 07h30 HE
|
Avenue Therapeutics
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
28 mars 2018 08h00 HE
|
Avenue Therapeutics
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics to Present at March Investor Conferences
05 mars 2018 08h00 HE
|
Avenue Therapeutics
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights
01 mars 2018 07h30 HE
|
Avenue Therapeutics
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference
06 févr. 2018 08h30 HE
|
Avenue Therapeutics
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain
02 janv. 2018 08h00 HE
|
Avenue Therapeutics
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
09 nov. 2017 07h30 HE
|
Avenue Therapeutics
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate...
Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
27 sept. 2017 08h00 HE
|
Avenue Therapeutics
NEW YORK, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that the first patient has been dosed in...
Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer)
15 août 2017 08h00 HE
|
Avenue Therapeutics
NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced the appointment of Joseph Vazzano as Vice...